Senescence is frequently described as a brake on uncontrolled growth. However, the research shows that this growth arrest is not necessarily the end of the story. The authors report that senescent states can become a launching pad for later relapse, particularly when tumor cells find ways to restore proliferative capacity over time.

Using experimental tumor models, the team traced the dynamics of senescence emergence and subsequent tumor outgrowth. Their data indicate that senescence does not simply silence cancer biology; it can reshape the tumor microenvironment and influence neighboring cells’ behavior. In this way, the “paused” cells act as an active component of the relapse process rather than passive end-stage tissue.

The study emphasizes mechanisms tied to how senescent cells communicate with their surroundings. Senescent tumor cells can alter signaling pathways through sustained secretion of factors that affect immune activity, inflammatory tone, and tissue remodeling. These changes can reduce the effectiveness of senescence-based suppression and help selected cancer cell populations regain fitness.

Importantly, the researchers connect relapse potential to the timing and persistence of senescence. Tumors that enter senescence-like arrest after oncogene shutdown may initially shrink, but residual, stress-adapted cell states can re-emerge as proliferative lesions. Thus, the same therapeutic maneuver can yield short-term benefit followed by long-term risk.

“Our findings highlight a paradox” is essentially the message of the paper: blocking an oncogene can provoke a senescent barrier, yet that barrier may also facilitate escape. The work therefore suggests that successful targeted therapy may require combining oncogene inactivation with strategies that prevent senescent cells from promoting relapse.

Beyond treatment implications, the research provides a framework for interpreting clinical patterns of tumor dormancy and recurrence following targeted interventions. It also raises the possibility that biomarkers of senescence state and senescence-associated secretory activity could help forecast relapse trajectories.

DOI: 10.1038/s41467-026-75021-9

ER+ breast cancer represents approximately 70% of all breast cancer cases worldwide and is frequently managed with endocrine therapies that disrupt estrogen signaling, a major driver of tumor growth. Although these therapies have improved patient outcomes, a significant challenge remains: a substantial fraction of tumors develop resistance, leading to relapse and metastatic progression. The recent approval and use of CDK4/6 inhibitors in combination with endocrine therapy have further enhanced progression-free survival in high-risk patients. However, not all patients benefit, spotlighting an urgent need to understand the molecular basis of this resistance phenomenon.

At the heart of the team’s investigation is the JNK signaling pathway, a critical cellular mechanism generally understood as both a modulator of stress-induced apoptosis and a regulator of cell cycle arrest. This pathway functions akin to an intracellular alarm system, activated upon cellular stressors such as DNA damage, oxidative stress, or cytotoxic therapies. Activation of the JNK pathway promotes processes that either halt cell proliferation or induce programmed cell death, mechanisms crucial for eliminating damaged or potentially oncogenic cells.

The researchers, led by Associate Professor Liz Caldon and Dr. Sarah Alexandrou, employed an innovative genome-wide CRISPR-Cas9 screen to systematically inactivate every gene across the genome in cultured ER+ breast cancer cells. This approach enabled them to pinpoint which genes, when silenced, confer resistance to combined endocrine and CDK4/6 inhibitor therapies. Strikingly, they discovered that disruption of multiple components of the JNK pathway, particularly the upstream kinase MAP2K7, allowed cancer cells to ignore therapeutic stress signals, continuing unabated proliferation and survival despite treatment.

Further validation involved analysis of tumor biopsies obtained from 78 ER+ breast cancer patients. Tumors exhibiting diminished JNK pathway activity correlated strongly with inferior therapy response and worse clinical outcomes. These findings collectively suggest that impaired JNK signaling functions as a molecular shield, permitting cancer cells to evade the cytostatic and cytotoxic effects of endocrine agents and CDK4/6 inhibitors by effectively silencing the stress alarms that would otherwise trigger senescence or apoptosis.

The revelation that the JNK pathway can act as a tumor suppressor contrasts with its previously held reputation in some cancer contexts as primarily tumor-promoting, underscoring the complexity of signal transduction networks within different cellular milieus. Within ER+ breast cancer, the balanced activity of the JNK pathway appears imperative; both hyperactivation and loss can perturb homeostasis, but loss notably drives therapeutic resistance. This dualistic role highlights a critical nuance in the pathway’s biology that can inform future therapeutic strategies.

Beyond mechanistic insights, the study offers translational promise. By developing biomarkers to assess JNK pathway functionality, clinicians could stratify patients prior to therapy initiation, identifying those unlikely to benefit from standard endocrine and CDK4/6 inhibitor regimens. This stratification would pave the way for personalized medicine, steering resistant patients toward alternative or adjunctive treatments and thereby optimizing clinical outcomes while minimizing unnecessary toxicity.

The Garvan team is spearheading ongoing research to unearth alternative therapeutic options tailored to cancers with suppressed JNK signaling. These efforts include screening for drugs capable of reactivating the pathway or exploiting vulnerabilities engendered by its silencing. The ultimate goal is a paradigm in which a patient’s tumor signaling profile guides bespoke treatment algorithms, maximizing efficacy and extending survival.

Importantly, this research underscores the value of integrating sophisticated genetic screening tools like CRISPR with patient-derived data to unravel complex biological resistance mechanisms. By combining high-throughput functional genomics with clinical sample analysis, the study establishes a robust framework for future oncology research aimed at overcoming drug resistance.

The implications of these findings extend beyond ER+ breast cancer, suggesting that similar stress response pathways may govern therapeutic resistance in other malignancies. As drug resistance remains a pervasive barrier in oncology, insights from the JNK pathway and its regulatory networks open new frontiers for investigation across cancer types.

This work was made possible through funding from diverse sources, including the National Breast Cancer Foundation and philanthropic awards, highlighting the synergistic role of public and private support in advancing cancer research. The team also acknowledges the important contributions of consumer advocates, emphasizing patient involvement in shaping impactful research agendas.

The promise embodied by this study is profound: in the near future, assessing the activity of cellular stress pathways like JNK may become routine in clinical oncology, informing decisions that tailor treatments to the molecular fingerprints of each tumor. For patients battling ER+ breast cancer, such precision could redefine prognosis and transform therapeutic landscapes.

Subject of Research: People

Article Title: JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

News Publication Date: 18-Aug-2025

Web References:
http://dx.doi.org/10.1186/s13046-025-03466-9

Image Credits: Garvan Institute

Keywords: Breast cancer, Drug resistance, Signal transduction, JNK pathway, Signaling pathways, Cancer treatments, Medical treatments, Cancer medication, Cancer, Estrogen receptors, Senescence

Melanoma, although accounting for only a small fraction of skin cancer cases globally, remains disproportionately lethal. It claims nearly 60,000 lives annually and is notorious for its aggressive tendency to metastasize, disseminating cancer cells from the primary tumor site to distant organs. This metastatic progression drastically reduces patient survival rates, with distant metastatic melanoma showing a survival rate of around 35% over five years, compared to an impressive 99% for localized disease. Countering metastasis has, therefore, become a focal point in oncology research, emphasizing the need to unravel cellular mechanisms that govern cancer cell dissemination.

The protein eIF2A, or eukaryotic initiation factor 2A, is traditionally characterized as a mediator of translation initiation, particularly under cellular stress conditions where it helps ribosomes to begin synthesizing proteins. However, the team led by Dr. Fátima Gebauer from the Centre for Genomic Regulation in Barcelona challenges this canonical role by demonstrating that in melanoma cells, eIF2A exerts a previously unappreciated influence on cellular motility, independent of protein synthesis. Their results were recently published in the prestigious journal Science Advances.

Employing a comparative approach using human skin cell lines with differing metastatic competencies, the researchers methodically diminished the functional activity of eIF2A. Their experiments revealed a striking phenomenon: suppressing eIF2A significantly impaired the growth of three-dimensional melanoma tumor spheres and severely hindered cell migration across wound-like scratches in culture dishes. Surpassing initial expectations, the inhibition of eIF2A barely affected overall protein production, indicating that its pro-migratory impact transcends its role in translation initiation.

To delve deeper into this paradox, the research team implemented innovative protein-interaction assays, effectively “fishing out” eIF2A along with its interacting molecular partners. This proteomic mapping unveiled a surprising affinity between eIF2A and multiple components of the centrosome — a critical cellular organelle responsible for organizing microtubules and orchestrating directional cell movement. Notably, when eIF2A levels were compromised, melanoma cells exhibited defects in orienting their centrosomes correctly, thereby losing their navigational cue during migration.

Further mechanistic studies illuminated how eIF2A stabilizes components of the centrosome, ensuring its proper alignment that allows cells to migrate efficiently. The protein’s carboxy-terminal tail appears to serve as an essential scaffolding element, maintaining the integrity of this intracellular compass. Functional truncation of eIF2A’s tail disrupted centrosomal orientation and markedly reduced cellular motility, pinpointing the tail as a promising, druggable target for therapeutic intervention.

Dr. Jennifer Jungfleisch, first author on the study, eloquently described the tail’s role as akin to “cement” that holds together critical elements of melanoma cells’ navigational apparatus. This analogy highlights the protein’s structural rather than enzymatic contribution to metastasis, marking a shift in how eIF2A’s function is conceptualized in the context of cancer cell biology.

Importantly, the study underscores that reliance on eIF2A emerges predominantly after malignant transformation, suggesting that targeting this protein might selectively impair cancer cells while sparing normal, healthy tissues. This tumor-specific dependency could offer a therapeutic window, minimizing collateral damage during treatment — a perennial challenge in oncology drug development.

However, translating these findings from cellular models to in vivo contexts remains an essential next step. The researchers caution that additional studies involving animal models and tissue systems are required to assess how disrupting eIF2A-mediated centrosomal functions impacts tumor spread and overall organismal health.

From a broader perspective, this revelation about eIF2A’s noncanonical role challenges existing paradigms in molecular oncology and cell biology. It exemplifies the complexity of protein functions within cancer cells and the importance of looking beyond traditional roles assigned to molecular players. Such insights could encourage the field to revisit and reevaluate other proteins previously pigeonholed into narrow functional categories.

The discovery of eIF2A’s pivotal role in melanoma cell migration not only shapes the future landscape of anti-metastatic therapies but also exemplifies the innovative spirit driving cancer research forward. As Dr. Gebauer aptly summarized, in an arena where many ostensibly promising targets have fallen short due to redundancy or toxicity, uncovering a protein that becomes indispensable specifically during metastasis is both rare and invaluable.

With metastasis accounting for the vast majority of cancer deaths, strategies that disrupt malignant cell escape and colonization of distant sites hold immense promise. The elucidation of eIF2A’s centrosome-centric function marks an important milestone in this quest, fostering optimism that novel drugs can intercept cancer dissemination at a fundamental biological level.

As the scientific community embraces these findings, continued interdisciplinary collaboration integrating cell biology, oncology, and translational medicine will be crucial. Advancing from molecular characterization to clinical application could eventually herald breakthroughs in melanoma prognosis and treatment, enhancing survival outcomes for thousands afflicted by this aggressive disease worldwide.

Subject of Research: Cells

Article Title: eIF2A regulates cell migration in a translation-independent manner

News Publication Date: 1-Aug-2025

Web References:
10.1126/sciadv.adu5668

Image Credits: Jennifer Jungfleisch/Centro de Regulación Genómica

Keywords: Melanoma, Skin cancer, Cancer

At the heart of this discovery lies RNA Polymerase I (Pol I), the enzyme responsible for transcribing ribosomal RNA genes—a vital step in the assembly of ribosomes, the cellular machinery that translates genetic codes into functional proteins. While aberrant ribosome biogenesis has historically been recognized as a hallmark of cancer, this study elucidates a previously unappreciated layer of complexity: the connection between rRNA synthesis and the regulation of RNA splicing, a process that enables a single gene to produce diverse protein variants through selective editing of precursor RNA transcripts.

Led by Dr. Marikki Laiho, an expert in Radiation Oncology and Molecular Radiation Sciences, the team demonstrated that pharmacological inhibition of Pol I instigates a unique cellular stress response that reprograms RNA splicing patterns in cancer cells. This reprogramming selectively impairs tumor growth by altering the production of protein isoforms crucial for cancer cell survival and proliferation. Central to this mechanism are ribosomal proteins RPL22 and its paralog RPL22L1, as well as the MDM4 protein, all of which participate in coordinating the dynamic crosstalk between ribosome biogenesis and splicing modulation.

The study employed BMH-21, a small molecule developed in collaboration with Johns Hopkins pharmacology specialists, to obstruct Pol I activity in a comprehensive panel of over 300 cancer cell lines. Strikingly, cancers harboring mutations in RPL22 or exhibiting elevated levels of RPL22L1 and MDM4 were particularly vulnerable to Pol I inhibition. Notably, these molecular alterations frequently occur in tumors characterized by mismatch repair deficiency (MMRd), a genetic condition involving defects in DNA repair pathways. MMRd leads to an accumulation of genomic mutations and is commonly observed in colorectal, gastric, and uterine cancers, which often show resistance to standard therapies.

Further extending their findings beyond cell culture, the researchers evaluated a novel Pol I inhibitor, BOB-42, in animal tumor models that recapitulate patient-derived malignancies bearing these critical genetic signatures. Treatment with BOB-42 resulted in significant tumor suppression, with reductions in tumor size reaching up to 77% in aggressive melanoma and colorectal cancer models. These preclinical successes highlight the therapeutic potential of targeting the rRNA synthesis-splicing axis in cancers that evade existing treatment modalities.

Beyond its tumor-suppressive effects, the study suggests a compelling link between altered splicing patterns induced by Pol I inhibition and enhanced tumor immunogenicity. By reshaping the protein landscape presented by cancer cells, changes in RNA splicing may unmask novel tumor antigens, potentially improving recognition by the immune system. Consequently, the combination of Pol I inhibitors with immunotherapy agents could synergize to overcome immune evasion, a major hurdle in effective cancer treatment.

Dr. Laiho elaborated on this innovative concept, emphasizing the dual role of the ribosomal protein RPL22. Traditionally viewed as a structural ribosomal component, RPL22 also exerts regulatory control over selective RNA splicing. This dual functionality underscores a deeper level of cellular regulation wherein rRNA synthesis and splicing are intimately coordinated to dictate cancer cell behavior. Such a paradigm shift in understanding ribosome-related oncogenic processes could lead to transformative advances in precision oncology.

The implications of this work extend beyond therapeutic targeting of Pol I. By delineating the molecular underpinnings of cancer cells’ sensitivity to rRNA synthesis inhibition, the study offers insights into the vulnerabilities of mismatch repair-deficient tumors, which are often characterized by high mutation burden and poor prognosis. Therapeutic strategies that exploit these vulnerabilities could fill an urgent need for more effective treatments in this patient population.

Moreover, the discovery paves the way for future investigations into the role of ribosomal proteins in RNA metabolism and how their dysregulation contributes to tumorigenesis. The intersection of ribosome biogenesis with RNA splicing regulation represents a fertile frontier for molecular oncology research, promising new biomarkers and drug targets for a variety of cancers.

This pioneering research involved a multidisciplinary team, including insights from experts in cancer biology, pharmacology, and radiation oncology. Their collaborative efforts, complemented by funding from prominent institutions such as the National Institutes of Health and private foundations, exemplify the concerted push toward unraveling complex cancer vulnerabilities.

Acknowledging the translational potential of their findings, the researchers hold intellectual property rights related to Pol I inhibitors, underscoring the practical ambitions of bringing these discoveries from bench to bedside. Future clinical trials assessing the safety and efficacy of compounds like BMH-21 and BOB-42 will be critical to validate their therapeutic promise in cancer patients.

The study profoundly redefines our understanding of how ribosomal RNA synthesis intricately controls tumor cell physiology, revealing an exploitable Achilles’ heel within cancer’s machinery. By co-opting fundamental processes of RNA production and splicing regulation, this research charts a novel course for developing targeted, mechanism-based cancer therapies that could markedly improve patient outcomes in malignancies refractory to current interventions.

Subject of Research: Cancer Biology, Ribosome Biogenesis, RNA Splicing, Therapeutic Targeting
Article Title: Ribosomal RNA Synthesis and RNA Splicing Interplay as a Novel Tumor-Suppressive Pathway in Mismatch Repair-Deficient Cancers
News Publication Date: June 18, 2024
Web References:

• Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel-cancer-center
• Department of Radiation Oncology and Molecular Radiation Sciences: https://www.hopkinsmedicine.org/radiation-oncology
• Cell Chemical Biology Journal: https://www.cell.com/cell-chemical-biology/home
  Image Credits: Courtesy of Cell Chemical Biology
  Keywords: Cells, Cancer Stem Cells, Ribosomal RNA, RNA Polymerase I, Mismatch Repair Deficiency, RPL22, RNA Splicing, Tumor Suppression, Immunotherapy, Cancer Therapeutics